Genetic Signatures

ASX Announcement 25 November 2026

US PATENT ALLOWANCE FOR GSS' IMPROVED ISOTHERMAL AMPLIFICATION TECHNOLOGY

Sydney, Australia, Genetic Signatures Limited (ASX: GSS) ("Genetic Signatures" or "the Company") is pleased to advise that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's US patent application No. 18/713,100, titled *Improved Isothermal Amplification*.

HIGHLIGHTS

- USPTO Notice of Allowance received for US patent application No. 18/713,100, *Improved Isothermal Amplification*
- Allowed claims protect a method, primer set and kit that enhance loop-mediated isothermal amplification (LAMP), with the aim of reducing false positives and increasing reaction efficiency and sensitivity
- Claims extend to multiplex reactions, bisulphite-treated nucleic acids compatible with the Company's proprietary 3base® chemistry, and the detection of a broad range of bacterial, viral, fungal and parasitic pathogens, including SARS-CoV-2 and seasonal coronaviruses
- The allowance expands Genetic Signatures' intellectual property portfolio in the USA, world's largest diagnostics market

About the allowed patent

LAMP is a rapid nucleic acid amplification method that operates at a single constant temperature, without the thermal cycling required for PCR. This makes it well suited to fast, lower-cost molecular testing. The broader adoption of LAMP has, however, been constrained by false positive results and variable sensitivity. The invention addresses these limitations generating additional RNA copies of the target during amplification, improving reaction efficiency and sensitivity compared with conventional LAMP.

The allowed claims cover:

- **Method**: A method of reducing false positives and increasing the efficiency and/or sensitivity of LAMP of a target nucleic acid, including multiplex reactions detecting more than one target
- **Primers**: A set of LAMP primers in which the F3 primer, or both the F3 and B3 primers, carry an RNA polymerase promoter at the 5' end
- **Kits**: A kit for detecting a target nucleic acid by LAMP containing the modified primers and the enzyme and reagent system, including multiplex kits

Dependent claims extend protection to bisulphite-treated target nucleic acids (3base®), the use of T7, T3 and SP6 promoters and polymerases, and the detection of a wide range of bacterial, viral, fungal and parasitic pathogens, including coronaviruses such as SARS-CoV-2, HKU-1, OC43 and NL63/229E.

Next steps

A Notice of Allowance confirms that the USPTO has examined the application and allowed it to proceed to grant. The patent is expected to be granted following payment of the issue fee, which is due by 19 January 2027 with a patent expiry in 2044.

Strategic significance

The allowance strengthens Genetic Signatures' intellectual property position in the United States, the world's largest molecular diagnostics market, and complements the patents protecting the Company's proprietary 3base® technology.

– END –

Announcement authorised by Genetic Signatures' Board of Directors.

For further information, see our website (www.geneticsignatures.com) or contact us:

Maria Halasz
Chief Executive Officer
maria.halasz@geneticsignatures.com
T: +61 (0)2 9870 7580

About Genetic Signatures Limited:

Genetic Signatures is a molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.